Erratum: STK17B promotes the progression of ovarian cancer

Erratum to: Ann Transl Med 2021;9:475.

This article (1) titled “STK17B promotes the progression of ovarian cancer” (doi: 10.21037/atm-21-601) unfortunately contains errors in Figure 3. “Megration” in Figure 3D,3E should be corrected as “migration”. Moreover, an icon error occurred in one image of Figure 3D selected to represent the migration assay of pcDNA3.1-STK17B and the negative control group. The red dot icon represents pcDNA3.1-STK17B instead of the negative control group. The image in Figure 3F representing the invading assays of the pcDNA3.1-STK17B group was duplicated accidentally.

Figure 3D and Figure 3F of the original article:

Correct Figure 3D and Figure 3F:

The correct version of Figure 3 is shown below:

Figure 3 Overexpression of STK17B accelerates ovarian cancer cells progression. (A) STK17B expression level increased. (B) Cell Counting Kit-8, (C) 5-ethynyl-20-deoxyuridine (×20), (D) scratch (×4), and (E,F) transwell (×10) assays were detected (the staining method is shown in Figure 2). **, P<0.01.

The authors confirmed this error did not significantly affect either the results or the conclusions of the paper.

Click here to view the updated version of the article.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Jiang L, Zhou J, Zhao S, et al. STK17B promotes the progression of ovarian cancer. Ann Transl Med 2021;9:475. [Crossref] [PubMed]